Back to Stocks

CVKD

Cadrenal Therapeutics, Inc.
8 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Cadrenal Therapeutics has reached a pivotal inflection point with its lead candidate, CAD-1005. The company successfully completed its End-of-Phase 2 meeting with the FDA, securing a clear regulatory roadmap for a randomized, blinded, placebo-controlled Phase 3 study.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the regulatory blueprint, Cadrenal's financial foundation is precarious. The company reported a net loss of $2.5 million for the quarter and ended March 31, 2026, with only $2.3 million in cash.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CVKD filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest 10-Q paints a picture of a company with high-value intellectual property but critical financial instability. The successful FDA alignment for CAD-1005 provides the 'what' and 'how' for success, but the balance sheet questions the 'if.' While the reduction in quarterly burn is a positive signal, it is overshadowed by the fact that the company cannot fund its own Phase 3 trials without significant external capital. Investors are now faced with a binary trade-off. The upside is a first-in-class therapy for a deadly disorder with orphan drug exclusivity. The downside is a classic biotech 'death spiral' where the need for cash leads to continuous dilution and potential delisting. The critical window for Cadrenal is the next six months, during which it must secure a strategic partner or a major financing round to bridge the gap to clinical execution.

Selected Quarter

Core Takeaway

The company has a validated clinical roadmap for its lead asset but lacks the capital to execute it without extreme dilution.

Investor Lens

The trade-off is between the high-conviction clinical potential of the 12-LOX platform and the high probability of severe equity dilution.

Watch Next

Announcement of a strategic partnership or a new capital raise to fund the 120-patient Phase 3 study.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.27Q1 '26 (10-K)+0.15Q2 '26 (10-Q)

Signal Timeline

28 of 31
Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression
90%
neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise
60%
bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition
70%
bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action
80%
bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression
90%
neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise
60%
bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition
70%
bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action
80%
bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression
90%
neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise
60%
bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition
70%
bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action
80%
bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression
90%
neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise
60%
bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition
70%
bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action
80%
bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression
90%
neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise
60%
bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition
70%
bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action
80%
bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression
90%
neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise
60%
bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition
70%
bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action
80%
bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression
90%
neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise
60%
bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition
70%
bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action
80%

Filing History

10-QMay 7, 2026
Expand Sequence

The latest 10-Q paints a picture of a company with high-value intellectual property but critical financial instability. The successful FDA alignment for CAD-1005 provides the 'what' and 'how' for success, but the balance sheet questions the 'if.' While the reduction in quarterly burn is a positive signal, it is overshadowed by the fact that the company cannot fund its own Phase 3 trials without significant external capital. Investors are now faced with a binary trade-off. The upside is a first-in-class therapy for a deadly disorder with orphan drug exclusivity. The downside is a classic biotech 'death spiral' where the need for cash leads to continuous dilution and potential delisting. The critical window for Cadrenal is the next six months, during which it must secure a strategic partner or a major financing round to bridge the gap to clinical execution.

10-KMar 31, 2026
Expand Sequence

Cadrenal Therapeutics is currently a high-risk, high-reward binary play centered on the transition to a Phase 3 pivotal trial for CAD-1005. The company has successfully pivoted its strategic focus and aligned management incentives through significant insider ownership. However, this operational discipline is currently overshadowed by a dire balance sheet and a looming cash crunch that threatens to derail clinical timelines. Investors are essentially weighing the potential of a first-in-class HIT treatment against the immediate risk of insolvency or massive shareholder dilution. While the regulatory designations provide a tailwind, the lack of current IP protection for tecarfarin and the missed primary endpoint in early CAD-1005 trials suggest that the path to the projected $825 million in peak revenue is fraught with significant clinical and legal hurdles.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.